$1 billion Ohmeda goes to Becton, Baxter and Datex-Engstrom
This article was originally published in Clinica
The BOC Group has finally been able to divest itself of the Ohmeda healthcare business, by splitting the company into three and selling to Becton Dickinson, Baxter International and Finnish company Instrumentarium's Datex-Engstrom.
You may also be interested in...
Executive appointments at MyoKardia, Scancell Holdings and Sutro Biopharma
The merger between Mylan and Pfizer’s Upjohn unit finally concluded on 16 November 2020, giving Viatris the go ahead for business. The newly-established company has announced receiving tentative approval for its 10mg pediatric dolutegravir tablets from the FDA under the PEPFAR program.
Johnson & Johnson believes personalization via digital holds the key to smoking cessation success as it launches in the UK its app-supported Nicorette QuickMist SmartTrack product.